Document is current
Any future updates will be listed below
-
Authors
Tsukada, Yuichiro https://orcid.org/0000-0001-6261-0152
Bando, Hideaki
Inamori, Koji
Wakabayashi, Masashi
Togashi, Yosuke https://orcid.org/0000-0001-9910-0164
Koyama, Shohei
Kotani, Daisuke https://orcid.org/0000-0002-4196-555X
Yuki, Satoshi
Komatsu, Yoshito https://orcid.org/0000-0002-1570-6802
Homma, Shigenori
Taketomi, Akinobu https://orcid.org/0000-0002-5238-3678
Uemura, Mamoru
Kato, Takeshi
Fukui, Makoto
Nakamura, Naoki
Kojima, Motohiro
Kawachi, Hiroshi
Kirsch, Richard
Yoshida, Tsutomu
Sato, Akihiro
Nishikawa, Hiroyoshi https://orcid.org/0000-0001-6563-9807
Ito, Masaaki
Yoshino, Takayuki https://orcid.org/0000-0002-0489-4756
-
Funding
Funding for this research was provided by:
Ono Pharmaceutical Co., Ltd.
- License Information
-
More Information
Article History
Received: 14 March 2024
Revised: 16 May 2024
Accepted: 17 May 2024
First Online: 4 June 2024
Competing interests
: HB has received research funding from AstraZeneca and Sysmex, and honoraria from Taiho Pharmaceutical and Eli Lilly Japan. MW has received honoraria from Nihon Medi-Physics Co., Ltd. YT has received honoraria from Ono Pharmaceutical, Bristol-Myers Squibb, Chugai Pharmaceutical, AstraZeneca, and MSD; and research grants from Ono Pharmaceutical, Bristol-Myers Squibb, Daiichi-Sankyo, Janssen, AstraZeneca, KOTAI Biotechnologies Inc, and KORTUC outside this study. SK has received research funding from Otsuka Pharmaceutical and Chugai Pharmaceutical. DK has received honoraria from Takeda, Chugai, Lilly, MSD, Ono, Taiho, Bristol-Myers Squibb, Daiichi-Sankyo, Pfizer, Novartis, Eisai, Seagen, Merck Biopharma, and Sysmex; research funding from Ono, MSD, Novartis, Servier, Janssen, IQVIA, Syneoshealth, Cimic, and Cimicshiftzero. SY has received honoraria from Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Bayer Yakuhin Ltd., Bristol-Myers Squibb K.K., Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Daiichi Sankyo Co., Ltd. AT has received research grants from Taiho Pharmaceutical, Astellas Pharma, Takeda Pharmaceutical, Bayer Yakuhin, and Ono Pharmaceutical. AS has received research funding from Taiho Pharmaceutical, Boehringer Ingelheim, Bayer, Chugai Pharma, Eisai, Ono Pharmaceutical, Takeda, Aspyerian Therapeutics, Pentax Medical Devices, and Daiichi Sankyo/UCB Japan. HN has received research funding and honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, MSD, and Bristol-Myers Squibb, and research funding from Daiichi-Sankyo, Kyowa Kirin, Zenyaku Kogyo, Taiho Pharmaceutical, Oncolys BioPharma, Debiopharm, Asahi-Kasei, Sysmex, Fujifilm, SRL, Astellas Pharmaceutical, Sumitomo Dainippon Pharma, and BD Japan outside this study. HN also serves as a board member and founder of Sustainable Cell Therapeutics and CELLIAN-BiCLO outside this study. TY has received research grants from Amgen, Chugai, Daiichi Sankyo, Eisai, FALCO Biosystems, Genomedia Inc., Molecular Health, MSD, Nippon Boehringer Ingelheim, Ono, Pfizer, Roche Diagnostics, Sanofi, Sysmex, and Taiho, honoraria from Chugai Pharma, Takeda Pharma, Merck, Bayer Yakuhin, Ono Pharmaceutical, and MSD K.K., and consulting fee from Sumitomo Corp.
: Written informed consent was obtained from all patients. The trial protocol was approved by the institutional review board of each participating site before the initiation of the study. The study was conducted in accordance with the tenets of the Declaration of Helsinki and Good Clinical Practice Guidelines after approval by the ethics board of each institution.
: Written informed consent for publication was obtained from the participants.
